论文部分内容阅读
目的观察多巴丝肼片联合金刚烷胺治疗帕金森病的临床疗效。方法选取2014年3月—2016年9月广元市第一人民医院收治的帕金森病患者60例,根据入院顺序分为对照组和观察组,每组30例。对照组患者予以多巴丝肼片治疗,观察组患者予以多巴丝肼片联合金刚烷胺治疗;两组患者均连续治疗1个月。比较两组患者临床疗效及治疗前后统一帕金森病评分量表(UPDRS)评分。结果观察组患者临床疗效优于对照组(P<0.05)。治疗前两组患者UPDRS总分及日常活动评分、精神行为评分、运动能力评分比较,差异无统计学意义(P>0.05);治疗后观察组患者UPDRS总分及日常活动评分、精神行为评分、运动能力评分低于对照组(P<0.05)。结论多巴丝肼片联合金刚烷胺治疗帕金森病的临床疗效确切,可有效改善患者日常活动及运动能力。
Objective To observe the clinical efficacy of dobesilazine combined with amantadine in the treatment of Parkinson’s disease. Methods Sixty patients with Parkinson’s disease who were treated in Guangyuan First People’s Hospital from March 2014 to September 2016 were selected and divided into control group and observation group according to admission sequence, 30 cases in each group. The patients in the control group were treated with dopprous hydrazine tablets, and the patients in the observation group were treated with dopprous hydrazine tablets and amantadine. Patients in both groups were treated continuously for 1 month. The clinical efficacy and the Unified Parkinson’s Disease Rating Scale (UPDRS) scores before and after treatment were compared between the two groups. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). There were no significant differences in UPDRS score, mental activity score and motor ability score between the two groups before treatment (P> 0.05). After treatment, UPDRS score, daily activity score, mental behavior score, Motor score was lower than that of control group (P <0.05). Conclusion The combination of dobesilazine and amantadine in the treatment of Parkinson’s disease has definite curative effect and can effectively improve the daily activities and motor ability of patients.